Eintrag weiter verarbeiten
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Gespeichert in:
| Zeitschriftentitel: | Cancer Research |
|---|---|
| Personen und Körperschaften: | , , , , |
| In: | Cancer Research, 73, 2013, 10, S. 2943-2948 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Huang, Yuhui Goel, Shom Duda, Dan G. Fukumura, Dai Jain, Rakesh K. Huang, Yuhui Goel, Shom Duda, Dan G. Fukumura, Dai Jain, Rakesh K. |
|---|---|
| author |
Huang, Yuhui Goel, Shom Duda, Dan G. Fukumura, Dai Jain, Rakesh K. |
| spellingShingle |
Huang, Yuhui Goel, Shom Duda, Dan G. Fukumura, Dai Jain, Rakesh K. Cancer Research Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy Cancer Research Oncology |
| author_sort |
huang, yuhui |
| spelling |
Huang, Yuhui Goel, Shom Duda, Dan G. Fukumura, Dai Jain, Rakesh K. 0008-5472 1538-7445 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/0008-5472.can-12-4354 <jats:title>Abstract</jats:title> <jats:p>The recent approval of Provenge has brought new hope for anticancer vaccine therapies. However, the immunosuppressive tumor microenvironment seems to impair the efficacy of vaccine therapies. The abnormal tumor vasculature creates a hypoxic microenvironment that polarizes inflammatory cells toward immune suppression. Moreover, tumors systemically alter immune cells' proliferation, differentiation, and function via secretion of growth factors and cytokines. For example, VEGF, a major proangiogenic cytokine induced by hypoxia, plays a critical role in immunosuppression via these mechanisms. Hence, antiangiogenic treatment may be an effective modality to potentiate immunotherapy. Here, we discuss the local and systemic effects of VEGF on tumor immunity and propose a potentially translatable strategy to re-engineer the tumor–immune microenvironment and improve cancer immunotherapy by using lower “vascular normalizing” doses of antiangiogenic agents. Cancer Res; 73(10); 2943–8. ©2013 AACR.</jats:p> Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy Cancer Research |
| doi_str_mv |
10.1158/0008-5472.can-12-4354 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8wMDA4LTU0NzIuY2FuLTEyLTQzNTQ |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8wMDA4LTU0NzIuY2FuLTEyLTQzNTQ |
| institution |
DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 DE-Ch1 |
| imprint |
American Association for Cancer Research (AACR), 2013 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2013 |
| issn |
0008-5472 1538-7445 |
| issn_str_mv |
0008-5472 1538-7445 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
huang2013vascularnormalizationasanemergingstrategytoenhancecancerimmunotherapy |
| publishDateSort |
2013 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Cancer Research |
| source_id |
49 |
| title |
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy |
| title_unstemmed |
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy |
| title_full |
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy |
| title_fullStr |
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy |
| title_full_unstemmed |
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy |
| title_short |
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy |
| title_sort |
vascular normalization as an emerging strategy to enhance cancer immunotherapy |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1158/0008-5472.can-12-4354 |
| publishDate |
2013 |
| physical |
2943-2948 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>The recent approval of Provenge has brought new hope for anticancer vaccine therapies. However, the immunosuppressive tumor microenvironment seems to impair the efficacy of vaccine therapies. The abnormal tumor vasculature creates a hypoxic microenvironment that polarizes inflammatory cells toward immune suppression. Moreover, tumors systemically alter immune cells' proliferation, differentiation, and function via secretion of growth factors and cytokines. For example, VEGF, a major proangiogenic cytokine induced by hypoxia, plays a critical role in immunosuppression via these mechanisms. Hence, antiangiogenic treatment may be an effective modality to potentiate immunotherapy. Here, we discuss the local and systemic effects of VEGF on tumor immunity and propose a potentially translatable strategy to re-engineer the tumor–immune microenvironment and improve cancer immunotherapy by using lower “vascular normalizing” doses of antiangiogenic agents. Cancer Res; 73(10); 2943–8. ©2013 AACR.</jats:p> |
| container_issue |
10 |
| container_start_page |
2943 |
| container_title |
Cancer Research |
| container_volume |
73 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792347443357024267 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:55:22.562Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Vascular+Normalization+as+an+Emerging+Strategy+to+Enhance+Cancer+Immunotherapy&rft.date=2013-05-15&genre=article&issn=1538-7445&volume=73&issue=10&spage=2943&epage=2948&pages=2943-2948&jtitle=Cancer+Research&atitle=Vascular+Normalization+as+an+Emerging+Strategy+to+Enhance+Cancer+Immunotherapy&aulast=Jain&aufirst=Rakesh+K.&rft_id=info%3Adoi%2F10.1158%2F0008-5472.can-12-4354&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792347443357024267 |
| author | Huang, Yuhui, Goel, Shom, Duda, Dan G., Fukumura, Dai, Jain, Rakesh K. |
| author_facet | Huang, Yuhui, Goel, Shom, Duda, Dan G., Fukumura, Dai, Jain, Rakesh K., Huang, Yuhui, Goel, Shom, Duda, Dan G., Fukumura, Dai, Jain, Rakesh K. |
| author_sort | huang, yuhui |
| container_issue | 10 |
| container_start_page | 2943 |
| container_title | Cancer Research |
| container_volume | 73 |
| description | <jats:title>Abstract</jats:title> <jats:p>The recent approval of Provenge has brought new hope for anticancer vaccine therapies. However, the immunosuppressive tumor microenvironment seems to impair the efficacy of vaccine therapies. The abnormal tumor vasculature creates a hypoxic microenvironment that polarizes inflammatory cells toward immune suppression. Moreover, tumors systemically alter immune cells' proliferation, differentiation, and function via secretion of growth factors and cytokines. For example, VEGF, a major proangiogenic cytokine induced by hypoxia, plays a critical role in immunosuppression via these mechanisms. Hence, antiangiogenic treatment may be an effective modality to potentiate immunotherapy. Here, we discuss the local and systemic effects of VEGF on tumor immunity and propose a potentially translatable strategy to re-engineer the tumor–immune microenvironment and improve cancer immunotherapy by using lower “vascular normalizing” doses of antiangiogenic agents. Cancer Res; 73(10); 2943–8. ©2013 AACR.</jats:p> |
| doi_str_mv | 10.1158/0008-5472.can-12-4354 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8wMDA4LTU0NzIuY2FuLTEyLTQzNTQ |
| imprint | American Association for Cancer Research (AACR), 2013 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2013 |
| institution | DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1 |
| issn | 0008-5472, 1538-7445 |
| issn_str_mv | 0008-5472, 1538-7445 |
| language | English |
| last_indexed | 2024-03-01T17:55:22.562Z |
| match_str | huang2013vascularnormalizationasanemergingstrategytoenhancecancerimmunotherapy |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 2943-2948 |
| publishDate | 2013 |
| publishDateSort | 2013 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Cancer Research |
| source_id | 49 |
| spelling | Huang, Yuhui Goel, Shom Duda, Dan G. Fukumura, Dai Jain, Rakesh K. 0008-5472 1538-7445 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/0008-5472.can-12-4354 <jats:title>Abstract</jats:title> <jats:p>The recent approval of Provenge has brought new hope for anticancer vaccine therapies. However, the immunosuppressive tumor microenvironment seems to impair the efficacy of vaccine therapies. The abnormal tumor vasculature creates a hypoxic microenvironment that polarizes inflammatory cells toward immune suppression. Moreover, tumors systemically alter immune cells' proliferation, differentiation, and function via secretion of growth factors and cytokines. For example, VEGF, a major proangiogenic cytokine induced by hypoxia, plays a critical role in immunosuppression via these mechanisms. Hence, antiangiogenic treatment may be an effective modality to potentiate immunotherapy. Here, we discuss the local and systemic effects of VEGF on tumor immunity and propose a potentially translatable strategy to re-engineer the tumor–immune microenvironment and improve cancer immunotherapy by using lower “vascular normalizing” doses of antiangiogenic agents. Cancer Res; 73(10); 2943–8. ©2013 AACR.</jats:p> Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy Cancer Research |
| spellingShingle | Huang, Yuhui, Goel, Shom, Duda, Dan G., Fukumura, Dai, Jain, Rakesh K., Cancer Research, Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy, Cancer Research, Oncology |
| title | Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy |
| title_full | Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy |
| title_fullStr | Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy |
| title_full_unstemmed | Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy |
| title_short | Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy |
| title_sort | vascular normalization as an emerging strategy to enhance cancer immunotherapy |
| title_unstemmed | Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1158/0008-5472.can-12-4354 |